Top Markets
Coin of the day
RetinalGenix Technologies Inc. RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc.

RTGN
Kedudukan dalam Saham #23316
RetinalGenix Technologies Inc. is a company dedicated to research and... RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
Harga Saham
$4.00
Disegerakkan terakhir: 2026-08-20
Modal Pasaran
$75.37M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
12.99%
Negara
US
Perdagangan RetinalGenix Technologies Inc. (RTGN)

Kategori

Hasil untuk RetinalGenix Technologies Inc. (RTGN)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada RetinalGenix Technologies Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi RetinalGenix Technologies Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE